CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aytu Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aytu Biopharma Inc
7900 E. Union Avenue, Suite 920
Phone: (720) 437-6580p:720 437-6580 DENVER, CO  80237  United States Ticker: AYTUAYTU
Business Summary
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s Rx Segment consists of prescription pharmaceutical products sold primarily through third party wholesalers. The Rx Segment primarily consists of two product portfolios: attention deficit hyperactivity disorder (ADHD) Portfolio and Pediatric Portfolio. The Company's prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of ADHD, Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8200 Educational services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Joshua R.Disbrow 49 1/27/2016 4/16/2015
Chief Financial Officer, Corporate Secretary, Treasurer Mark K.Oki 55 5/5/2022 1/17/2022
Chief Commercial Officer GregPyszczymuka 45 1/1/2022 1/1/2022
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Innovus Pharmaceuticals, Inc. 8845 Rehco Road San Diego CA United States
Vyrix Pharmaceuticals Inc Suite 925, 5445 DTC Parkway GREENWOOD VILLAGE CO United States
Semprae Laboratories, Inc. 160 Pehle Ave Saddle Brook NJ United States
Neos Therapeutics Inc 2940 N State Highway 360 Ste 400 Grand Prairie TX United States

Business Names
Business Name
AYTU
Aytu Therapeutics LLC
AYTUD
13 additional Business Names available in full report.

General Information
Number of Employees: 99 (As of 9/16/2024)
Outstanding Shares: 6,148,993 (As of 9/16/2024)
Shareholders: 187
Stock Exchange: NASD
Federal Tax Id: 470883144
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, October 30, 2024